Shares of CryoPort, Inc. (NASDAQ:CYRX) have been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. CryoPort’s rating score has declined by 50% in the last three months as a result of a number of analysts’ upgrades and downgrades.

Brokerages have set a 12-month consensus price objective of $5.33 for the company and are expecting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned CryoPort an industry rank of 192 out of 265 based on the ratings given to its competitors.

Several research analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price (up previously from $4.50) on shares of CryoPort in a research note on Monday, June 26th. Cowen and Company assumed coverage on shares of CryoPort in a research note on Friday, June 16th. They issued an “outperform” rating and a $5.50 target price on the stock. Finally, ValuEngine raised shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th.

COPYRIGHT VIOLATION NOTICE: “Zacks: CryoPort, Inc. (CYRX) Given $5.33 Average Target Price by Brokerages” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at

CryoPort (CYRX) traded down 1.03% during mid-day trading on Thursday, hitting $4.79. 26,115 shares of the company were exchanged. The stock’s market cap is $114.84 million. CryoPort has a 12-month low of $1.63 and a 12-month high of $4.95. The company has a 50 day moving average of $3.91 and a 200 day moving average of $3.27.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. CryoPort had a negative net margin of 137.99% and a negative return on equity of 104.79%. The firm had revenue of $2.71 million for the quarter, compared to analyst estimates of $2.59 million. On average, equities research analysts expect that CryoPort will post ($0.72) earnings per share for the current fiscal year.

CryoPort Company Profile

Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

Get a free copy of the Zacks research report on CryoPort (CYRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related stocks with our FREE daily email newsletter.